Free Articles

Share This Page

Now on Twitter!

Follow us: ChinaBio

In the News

"Mr. Bio in China"

>> New! Greg Scott quoted on Bloomberg

>> Greg Scott interviewed by Mendelspod (podcast)

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

Subscriber Content

These articles are provided free to all readers. Other free articles are available in Week in Review, In My Opinion, and Education Center. To have access to all of our articles, click here...

Recent Articles

The Week in Review: Are WuXi PharmaTech and ShangPharma Takeover Targets? Feb 4, 2012: WuXi PharmaTech and ShangPharma are both attractive M&A targets, with higher profit margins and lower PE ratios than their US competitors; Cardinal Health will make $90 million in China acquisitions to bolster its drug distribution coverage; Tianjin Tasly Pharma and SemBioSys Genetics of Canada received business licenses for their China JV; Transgene formed a scientific cooperation program with three European institutions and Fudan University Shanghai Cancer Center; the Beijing FDA added new categories of drugs for fast-track status; Steve Yang, AstraZeneca’s VP for R&D in Asia, says the company’s China R&D operation aims to “transform how we do R&D;” AstraZeneca announced another 7,300 layoffs in the US and Europe as it adds activities in China; and Frontage Labs announced its completed a Phase I trial of a China botanical drug in the US. More details….

Stock Symbols: (NYSE: WX) (NYSE: SHP) (NYSE: CAH) (SHA: 600535) (TSX: SBS) (Euronext: TNG) (NYSE: AZN)

Share this with colleagues:

The Week in Review: Seven China Researchers Land $650,000 Howard Hughes Research Grants Jan 28, 2012: Seven early-career China researchers landed $650,000 grants from the Howard Hughes Medical Institute, four of them are part of Beijing’s National Institute of Biological Sciences; EntreMed landed $10 million from a group of investors with China roots; Saladax Biomedical believes China will be a big market for the company’s diagnostic assays; SuperNova Diagnostics® is developing a point of care platform based on LCD technology; and Syneron Medical received SFDA approval for five aesthetic dermatology devices. More details….

Stock Symbols: (NSDQ: ENMD) (NSDQ: ELOS)

Share this with colleagues:

For Saladax Biomedical, China Could Be the Largest Market Jan 27, 2012: Saladax Biomedical, a Bethlehem, Pennsylvania medical diagnostic reagent developer and manufacturer, believes China will be a big part of the company’s future. Edward L. Erickson, CEO of Saladax, told ChinaBio® Today in an exclusive interview, “The volume of the market in China for our products appears to be larger than the US and Europe put together.” Saladax makes MyCare™ therapeutic dose management products, and its major product is currently My5-FU™, a dose management test for 5-FU chemotherapy. More details....

Share this with colleagues:

SuperNova Developing Point of Care Diagnostics Technology Jan 24, 2012: SuperNova Diagnostics®, a US-based, global diagnostics company with deep China connections, is developing a point of care platform based on LCD technology. The device combines ease of use with low cost – a seemingly unbeatable combination. And it is now moving toward production. “It’s going to be a good year for Supernova Diagnostics,” said Neil Campbell, CEO and Co-Founder of the company in an exclusive ChinaBio® Today interview. “There aren’t a lot of technologies out there that can do what we do.” More details....

Share this with colleagues:

The Week in Review: Xizang Haisco Pharma Completes $127 Million IPO Jan 21, 2012: Xizang Haisco Pharma, a Tibetan TCM company, staged a $127 million IPO in Shenzhen; Sanjiu Medical and Pharma expects to spend between $94.7 and $110.5 million to buy Shandong Shunfeng Pharma; Da An Gene formed a diagnostics JV with Life Technologies of San Diego; Jiangsu Kanion Pharma transferred the global ex-China rights for three oncology drug candidates to NewGen Therapeutics of California; ShangPharma reached the first milestone in its mAb partnership with Jiangsu Hengrui Medicine; Quintiles opened a back office center in Dalian, a northeast China city; Novartis received SFDA approval for Lucentis, a treatment for wet AMD, and will launch its diabetes drug, Galvus, in China; Xiamen Innovax Biotech was granted SFDA approval for a hepatitis E vaccine; and Drs. Zhen-Yi Wang and Zhu Chen were awarded a prestigious US prize for their groundbreaking work with a leukemia sub-type. More details….

Stock Symbols: (SHE: 002653) (SHE: 000999) (SHE: 002030) (NSDQ: LIFE) (SHA: 600557) (NYSE: SHP) (NYSE: NVS)

Share this with colleagues:

China Scientists Given US Award for Cancer Breakthrough Jan 20, 2012: Two China scientists have been awarded a prestigious US prize for their groundbreaking work with a form of leukemia. By combining traditional Chinese medicine and western approaches, they increased the five-year survival rate of acute promyelocytic leukemia (APL) from 25% to an astonishing 95%. In recognition of their contribution, Drs. Zhen-Yi Wang and Zhu Chen were named recipients of the 7th Szent-Györgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research in the US. More details....

Share this with colleagues:

China Excitement at J.P. Morgan Healthcare Conference Jan 14, 2012: The annual J.P. Morgan Healthcare extravaganza, held last week in San Francisco, was buzzing with excitement about China. Optimism was running high and, best of all, participants were discussing real deals. It was the second year the conference included a China-specific track, giving 15 China-centered life science companies a chance to present their stories. The room was often filled to its 200-seat capacity, forcing some attendees to stand at the back and even more to peer in through the glass doors at the back of the room. The strong sense of positive energy evident throughout J.P. Morgan this year was even more apparent in the China Reception following the company presentations. More details....

Share this with colleagues:

The Week in Review: China Unveils Biotech Development Plan 2010-2020 Jan 7, 2012: China’s MOST issued the National Program on Bioscience Technology Development 2010-2020, establishing a set of very specific goals for developing a world-class biotech industry in China; Vivo Ventures closed its $375 million Vivo Ventures VII fund that will invest in China and US healthcare companies, with a particular bias toward cross-border partnerships; AstraZeneca plans to expand its branded generics business in China through M&A with China pharmas; ProteoTech will collaborate with GSK China to develop a Parkinson’s disease drug; China Kanghui Holdings received FDA approval for two artificial joint replacements; Darren Ji, MD, PhD, stepped down as CEO of PharmaLegacy and will now be setting up and managing new ventures in China and Asia; and Ascletis received a $1.6 million R&D grant from the Hangzhou National Hi-Tech Industrial Development Zone. More details….

Stock Symbols: (NYSE: AZN) (NYSE: GSK) (NYSE: KH)

Share this with colleagues:

China Announces Major Program for Biotechnology 2010-2020 Jan 5, 2012: To establish itself in the global front rank of biotech innovation, China has issued the National Program on Bioscience Technology Development 2010-2020. The program, which was issued by the Ministry of Science and Technology, establishes a series of ambitious, very specific goals for developing a world-class biotech industry in China. As a starter, China wants to produce three to five top biotech scientists with international reputations and Nobel Prize potential by 2020. More details....

Share this with colleagues:

The Week in Review: China Events at J.P. Morgan Healthcare Conference Dec 31, 2011: The 2012 J.P. Morgan Healthcare Conference includes several China-related events, which we describe; Harbin Pharma was given an official go-ahead to complete an $870 million corporate restructuring with its parent, Harbin Pharmaceutical Group; China Health Resource retained legal counsel to facilitate an international acquisition strategy; China announced new Foreign Direct Investment Guidelines that will encourage foreigners to invest in China biotechnology companies; and Yunnan Baiyao Group began operations in its new $396 million production facility. More details….

Stock Symbols: (SHA: 600664) (OTCBB: CHRI) (SHE: 000538)

Share this with colleagues: